Common peptide questions
Questions about the compounds, the kinds of studies behind them and what remains unresolved.
Are these approved medicines?
BPC-157, TB-500 and GHK-Cu have no FDA-approved drug product. GHK-Cu’s use as a cosmetic ingredient is a separate context; a cosmetic ingredient does not acquire drug approval through everyday use. The compound pages keep this distinction beside the relevant studies.
FDA’s safety-risk page, current as of April 22, 2026, lists BPC-157, TB-500 and injectable GHK-Cu as nominated but withdrawn. Withdrawal does not mean clearance, approval or permission to compound. The concerns printed beside those entries remain relevant.
What does preclinical mean?
Preclinical findings come from work before a treatment has been shown to help people, often in cell cultures or animal models. Such experiments can identify a possible mechanism or a reason to study a compound further. They cannot establish how well a treatment works for a person.
For example, the BPC-157 Achilles-tendon experiment measured healing in rats. The species, injury and study conditions are part of the result. Replacing those details with a broad claim about human recovery would go beyond the experiment.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a capped seven-amino-acid fragment based on the forty-three-amino-acid parent protein. The FDA assessment treats them as different substances and found no published human TB-500 study in its review.
The healthy-volunteer trial often cited in this discussion tested full-length thymosin beta-4. It examined early tolerability, not the fragment’s ability to heal an injury. A similar sequence does not make two substances clinically interchangeable.
Did the hair trial test GHK-Cu alone?
The six-month trial in forty-five men tested free GHK combined with 5-aminolevulinic acid. Hair counts improved more with the active combination than with placebo. The study did not isolate the effect of GHK-Cu, and hair thickness did not change.
This matters because a result for combined ingredients cannot identify each ingredient’s contribution. It also cannot support a different route, such as an injection. The GHK-Cu page separates the combination trial from the skin and delivery literature.
Does a small safety study show safety?
A small study can record what happened to its participants. It usually cannot detect uncommon harms or answer questions about years of exposure. The two-adult BPC-157 safety pilot is an example of a narrow observation, not a general safety guarantee.
FDA’s concerns about immune reactions and peptide quality are a different kind of evidence from an observed side-effect rate. Both deserve context. A lack of reported problems in a small sample cannot settle those concerns or provide a reliable interaction list.
Can online experiences prove that a compound works?
Community reports can describe hopes, perceived changes and suspected reactions. They are anecdotal, not clinical evidence. The exact preparation, other care, expectations and natural recovery may be uncertain. Those accounts cannot establish what caused a change or how often it occurs.
A comparison group helps address some of these problems, but its design still matters. The number of participants, the outcome measured and the length of follow-up determine which conclusions a clinical study can support.
Can these pages supply a personal plan?
There are no personal doses, schedules or suggested combinations here. Study amounts belong to the named experiments, and animal amounts do not translate directly into human instructions. An individual decision also depends on health history and an appropriate clinical assessment.
The point of those questions is to keep a conclusion proportionate to its source. They can identify a mismatch between a claim and a paper even when the paper itself reports a positive result.
The comparison offers questions to bring to a claim: which molecule, which route, which study setting and which outcome? The contact page explains why this site cannot assess symptoms or provide treatment. The sources support further examination of the studies themselves.